baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Voyager Therapeutics/ US92915B1061 /

2024-04-24 9:59:55 PM	Chg. -0.08	Volume	Bid-	Ask-	High	Low
7.57USD	-0.98%	7,112 Turnover: 53,569.47	-Bid Size: -	-Ask Size: -	7.64	7.45

GlobeNewswire 04-22 Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Th...

GlobeNewswire 04-16 Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration ...

GlobeNewswire 03-28 Inventiva announces the nomination of Andre Turenne as Director

GlobeNewswire 03-26 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 03-13 Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

GlobeNewswire 02-29 PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

GlobeNewswire 02-28 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

GlobeNewswire 02-26 Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Atax...

GlobeNewswire 02-21 Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

GlobeNewswire 02-20 Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for A...

GlobeNewswire 01-05 Voyager Therapeutics Announces Pricing of Public Offering

GlobeNewswire 01-04 Voyager Therapeutics Announces Proposed Public Offering

GlobeNewswire 01-03 Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 01-02 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...

GlobeNewswire 2023-12-06 Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Scler...

GlobeNewswire 2023-12-01 Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

GlobeNewswire 2023-11-06 Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results

GlobeNewswire 2023-10-30 Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

GlobeNewswire 2023-09-25 Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference

GlobeNewswire 2023-09-07 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2023-08-30 Voyager Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 2022-03-22 Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer

GlobeNewswire 2022-03-08 Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

GlobeNewswire 2022-03-08 Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to ...

GlobeNewswire 2022-02-10 Voyager Therapeutics to Participate in Upcoming Investor Conferences

Voyager Therapeutics/ US92915B1061 /

If you wish to receive reply to your feedback, please provide your email address.